291 related articles for article (PubMed ID: 31391554)
1. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase.
Skrott Z; Majera D; Gursky J; Buchtova T; Hajduch M; Mistrik M; Bartek J
Oncogene; 2019 Oct; 38(40):6711-6722. PubMed ID: 31391554
[TBL] [Abstract][Full Text] [Related]
2. The interaction of disulfiram and H
Read E; Milford J; Zhu J; Wu L; Bilodeau M; Yang G
Toxicol Appl Pharmacol; 2021 Sep; 426():115642. PubMed ID: 34242567
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Jiao Y; Hannafon BN; Ding WQ
Anticancer Agents Med Chem; 2016; 16(11):1378-1384. PubMed ID: 27141876
[TBL] [Abstract][Full Text] [Related]
4. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
5. S-methyl-N,N-diethylthiocarbamate sulfoxide and S-methyl-N,N-diethylthiocarbamate sulfone, two candidates for the active metabolite of disulfiram.
Mays DC; Nelson AN; Lam-Holt J; Fauq AH; Lipsky JJ
Alcohol Clin Exp Res; 1996 May; 20(3):595-600. PubMed ID: 8727261
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of Aldehyde Dehydrogenase by Disulfiram in the Presence and Absence of Lipoic Acid or Dihydrolipoic Acid: An in Vitro Study.
Bilska-Wilkosz A; Górny M; Iciek M
Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31426424
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
[TBL] [Abstract][Full Text] [Related]
9. S-methyl N,N-diethylthiocarbamate sulfone, a potential metabolite of disulfiram and potent inhibitor of low Km mitochondrial aldehyde dehydrogenase.
Mays DC; Nelson AN; Fauq AH; Shriver ZH; Veverka KA; Naylor S; Lipsky JJ
Biochem Pharmacol; 1995 Mar; 49(5):693-700. PubMed ID: 7887984
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells.
Loffelmann M; Škrott Z; Majera D; Štarha P; Kryštof V; Mistrík M
Eur J Med Chem; 2023 Dec; 261():115790. PubMed ID: 37690264
[TBL] [Abstract][Full Text] [Related]
11. In vivo inhibition of aldehyde dehydrogenase by disulfiram.
Lipsky JJ; Shen ML; Naylor S
Chem Biol Interact; 2001 Jan; 130-132(1-3):93-102. PubMed ID: 11306034
[TBL] [Abstract][Full Text] [Related]
12. Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis.
Hamblin KA; Flick-Smith H; Barnes KB; Pereira-Leal JB; Surkont J; Hampson R; Atkins HS; Harding SV
Int J Antimicrob Agents; 2019 Jul; 54(1):85-88. PubMed ID: 31029736
[TBL] [Abstract][Full Text] [Related]
13. Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells.
Chen SY; Chang YL; Liu ST; Chen GS; Lee SP; Huang SM
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918312
[TBL] [Abstract][Full Text] [Related]
14. Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
Kang X; Jadhav S; Annaji M; Huang CH; Amin R; Shen J; Ashby CR; Tiwari AK; Babu RJ; Chen P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376016
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
16. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram.
Lam JP; Mays DC; Lipsky JJ
Biochemistry; 1997 Nov; 36(44):13748-54. PubMed ID: 9354647
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase by S-methyl N,N-diethylthiolcarbamate sulfoxide, a new metabolite of disulfiram.
Hart BW; Faiman MD
Biochem Pharmacol; 1992 Feb; 43(3):403-6. PubMed ID: 1311578
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
[TBL] [Abstract][Full Text] [Related]
20. Overview--in vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites.
Lipsky JJ; Shen ML; Naylor S
Chem Biol Interact; 2001 Jan; 130-132(1-3):81-91. PubMed ID: 11306033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
